SGX up on Novartis Bcr-Abl inhibitor deal

SGXP gained $0.92 (12%) to $8.79 on Tuesday after announcing that it partnered with Novartis (NVS; SWX:NOVN) to develop and commercialize SGXP's preclinical Bcr-Abl inhibitors to treat drug-resistant ...